New EAS Consensus Highlights Advances in Pediatric FH Care
European Atherosclerosis Society shared a post on LinkedIn about a recent article by Albert Wiegman et al., published in European Heart Journal։
“Familial hypercholesterolaemia (FH) is a common genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol (LDL-C) concentrations, which increase the risk of premature atherosclerotic cardiovascular disease (ASCVD).
FH affects around 1 in 300 people worldwide, while the more severe form, Homozygous FH (HoFH), affects about 1 in 300,000 people and can lead to serious cardiovascular complications already in childhood.
Early diagnosis and treatment can dramatically improve – and even normalize – life expectancy.
Yet, fewer than 10% of affected children in Europe are currently identified.
The European Atherosclerosis Society (EAS) consensus statement on FH in children and adolescents highlights:
- Improved diagnostic criteria
- Earlier treatment initiation – sometimes from age 6
- Lower LDL-C treatment targets
- New lipid-lowering therapies
- Updated treatment algorithms
- Better transition from paediatric to adult care.
The statement emphasizes one key message: reducing lifelong exposure to high LDL-C is critical to protecting cardiovascular health from an early age.”
Title: Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement
Authors: Albert Wiegman, Mafalda Bourbon, Tomas Freiberger, Samuel S Gidding, Susanne Greber-Platzer, Urh Groselj, Kirsten B Holven, Lisa C Hudgins, Steve E Humphries, Barbara A Hutten, Daiana Ibarretxe, Cristina Pederiva, Noel Peretti, Frederick J Raal, Uma Ramaswami, Veronika Sanin, Raul D Santos, Elisabeth Steinhagen-Thiessen, Gerald F Watts, Rosie Perkins, Marianne Benn, Christoph J Binder, Stefano Romeo, Jeanine E Roeters van Lennep

Stay updated with Hemostasis Today.
-
Aug 26, 2026, 17:38Stephan A Mayer: Early Imaging Reveals Higher Risk of Hematoma Expansion After ICH
-
Aug 26, 2026, 17:09Kemal Karaagac: NOACs May Offer Cognitive and Clinical Benefits in AF With Alzheimer’s Disease
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension